Monoclonal antibody aiming at neuraminidase of human influenza virus as well as preparation method and application of monoclonal antibody

By developing high-affinity monoclonal antibodies that specifically recognize human influenza virus NA proteins, the shortcomings in the prevention and treatment of human influenza virus NA proteins in the prior art have been solved, and the effect of efficient neutralizing human influenza viruses has been achieved, with significant clinical Application value.

CN119060174AActive Publication Date: 2024-12-03INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Patent Information

Application Number
CN202411329200.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03
Estimated Expiration
2044-09-23

AI Technical Summary

Technical Problem

The prior art is difficult to develop monoclonal antibodies with high affinity and high activity against the neuraminidase (NA) protein of human influenza virus, resulting in shortcomings in preventing and treating human influenza virus infection.

Method used

By screening and developing a monoclonal antibody that specifically recognizes the NA protein of human influenza virus, its heavy and light chain variable region amino acid sequences have high identity, combining the ability to efficiently neutralize human influenza viruses, for prevention and treatment Human flu virus infection.

Benefits of technology

It has achieved high affinity binding and neutralization ability for human influenza virus NA protein, and has high potential for detection and effective prevention or treatment of human influenza virus infection, and has great clinical application prospects and value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005056956770000091
    Figure BDA0005056956770000091
  • Figure BDA0005056956770000101
    Figure BDA0005056956770000101
  • Figure BDA0005056956770000111
    Figure BDA0005056956770000111
Patent Text Reader

Abstract

The invention relates to a monoclonal antibody specifically binding to human influenza virus neuraminidase (NA) or an antigen binding fragment thereof, a related product thereof, and a preparation method and application thereof. According to the present invention, the monoclonal antibody or the antigen binding fragment thereof can be combined with the human influenza virus NA protein with the high affinity, and can neutralize the human influenza virus strain with the high neutralizing activity so as to inhibit the infection, such that the huge potential application value is provided in the clinical treatment, prevention and / or detection of the human influenza virus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunology and molecular virology, and in particular to a monoclonal antibody against human influenza virus neuraminidase (NA) protein, and a preparation method and application thereof. Background Art

[0002] Influenza virus belongs to the family Orthomyxoviridae and the genus Influenzavirus. It is an enveloped, polymorphic, segmented, single-stranded negative-sense RNA virus. Influenza virus can be divided into four subtypes: A, B, C, and D according to the antigenicity of its nucleoprotein (NP) and matrix protein (MP). Influenza virus type A can be divided into multiple subtypes according to the antigenicity of its surface proteins hemagglutinin (HA) and neuraminidase (NA). Currently, HA protein includes 18 subtypes and NA protein includes 11 subtypes. Influenza virus can cause acute respiratory tract infection, with symptoms such as acute fever, cough, sore throat, body pain and fatigue. In severe cases, it can lead to severe illness or even death. In addition, some highly pathogenic strains such as H5N1 and H5N6 can also cause serious consequences and high mortality.

[0003] The hemagglutinin protein (HA) and influenza neuraminidase (NA) on the surface of influenza virus are important antigenic proteins. Humans can produce antibodies against HA and NA after being infected with influenza virus. Such antibodies play an important role in preventing and treating viral infections. Therefore, screening for high-neutralizing antibodies against human influenza virus HA or NA proteins to effectively prevent and / or treat human influenza virus is an important goal in the field of influenza virus prevention and treatment. Summary of the invention

[0004] Purpose of the Invention

[0005] In view of the problems existing in the prior art, the object of the present invention is to provide a monoclonal antibody having high affinity for human influenza virus NA protein and showing high neutralizing activity thereto, and related products and preparation methods and uses thereof.

[0006] Solution

[0007] In order to achieve the above-mentioned object, the present invention has discovered a monoclonal antibody after a large number of experimental studies, which can specifically recognize and target human influenza virus neuraminidase, and show high antigen binding activity and high ability to neutralize human influenza virus. Therefore, the monoclonal antibody of the present invention is particularly suitable for preventing and / or treating human influenza virus infection.

[0008] Specifically, the present invention provides the following technical solutions:

[0009] In a first aspect, the present invention provides a monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human influenza virus neuraminidase (NA), comprising a heavy chain variable region and / or a light chain variable region, wherein:

[0010] The heavy chain variable region comprises:

[0011] HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively;

[0012] The light chain variable region comprises:

[0013] The amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 respectively.

[0014] Preferably, the monoclonal antibody or antigen-binding fragment thereof comprises:

[0015] a heavy chain variable region comprising, or consisting of, the amino acid sequence of SEQ ID NO:7, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO:7; and,

[0016] A light chain variable region comprising, or consisting of, the amino acid sequence shown in SEQ ID NO:8, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:8.

[0017] In a preferred embodiment, the monoclonal antibody or antigen-binding fragment thereof comprises:

[0018] A heavy chain variable region, the amino acid sequence of which is shown in SEQ ID NO:7; and,

[0019] The amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.

[0020] In addition, the monoclonal antibody or antigen-binding fragment thereof further comprises a constant region; preferably, the constant region is any one selected from the following: a constant region of an IgG, IgA or IgM antibody.

[0021] In a preferred embodiment, the monoclonal antibody or its antigen-binding fragment further comprises a heavy chain constant region and / or a light chain constant region; preferably, the amino acid sequence of the heavy chain constant region is as shown in SEQ ID NO:9; and, preferably, the amino acid sequence of the light chain constant region is as shown in SEQ ID NO:10.

[0022] In some preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof comprises:

[0023] a heavy chain comprising, or consisting of, the amino acid sequence of SEQ ID NO: 11, or an amino acid sequence having at least 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence of SEQ ID NO: 11; and,

[0024] A light chain comprising, or consisting of, the amino acid sequence shown in SEQ ID NO:12, or an amino acid sequence having at least 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:12.

[0025] Further preferably, the monoclonal antibody or antigen-binding fragment thereof comprises:

[0026] A heavy chain, the amino acid sequence of which is shown in SEQ ID NO: 11; and

[0027] The light chain has an amino acid sequence as shown in SEQ ID NO:12.

[0028] In certain preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof further has a leader sequence at the N-terminus of its heavy chain variable region and / or light chain variable region; preferably, the leader sequence has an amino acid sequence as shown in SEQ ID NO: 13, and further preferably, the leader sequence is encoded by a nucleotide sequence as shown in SEQ ID NO: 26.

[0029] In some feasible embodiments, the antigen-binding fragment of the monoclonal antibody is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single chain antibody, human antibody, chimeric antibody or bispecific or multispecific antibody.

[0030] The monoclonal antibody or antigen-binding fragment thereof of the present invention can specifically bind to the NA protein of human influenza virus and has a high neutralizing ability against human influenza virus, thereby being able to prevent and / or treat infection by human influenza virus.

[0031] In a second aspect, the present invention provides a polynucleotide encoding the monoclonal antibody or antigen-binding fragment thereof as described in the first aspect. The polynucleotide is not limited by the method of its production and can be obtained by genetic engineering recombination technology or chemical synthesis method.

[0032] In a possible embodiment, the polynucleotide is a set of polynucleotides.

[0033] In some preferred embodiments, the polynucleotide set comprises:

[0034] (I) a first polynucleotide encoding HCDR1, HCDR2 and HCDR3 of the heavy chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, preferably, the first polynucleotide is a DNA molecule comprising the nucleotide sequences as shown in SEQ ID NO: 14, 15, 16 (which can encode the amino acid sequences as shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively) or its corresponding mRNA molecule; and,

[0035] (II) A second polynucleotide encoding LCDR1, LCDR2 and LCDR3 of the light chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention. Preferably, the second polynucleotide is a DNA molecule comprising a nucleotide sequence as shown in SEQ ID NO: 17, 18, 19 (which can encode an amino acid sequence as shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, LCDR1, LCDR2 and LCDR3, respectively) or its corresponding mRNA molecule.

[0036] Further preferably, the polynucleotide group comprises:

[0037] (I) a first polynucleotide encoding the heavy chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, preferably, the first polynucleotide is a DNA molecule comprising the nucleotide sequence as shown in SEQ ID NO: 20 (which can encode the heavy chain variable region of the amino acid sequence as shown in SEQ ID NO: 7) or its corresponding mRNA molecule; and,

[0038] (II) a second polynucleotide encoding the light chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, preferably, the second polynucleotide is a DNA molecule comprising the nucleotide sequence as shown in SEQ ID NO: 21 (which can encode the light chain variable region of the amino acid sequence as shown in SEQ ID NO: 8) or its corresponding mRNA molecule;

[0039] Preferably, the first polynucleotide encoding the heavy chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention and / or the second polynucleotide encoding the light chain variable region of the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a nucleotide sequence encoding a leader sequence at the 5' end, preferably, the nucleotide sequence encoding the leader sequence is as shown in SEQ ID NO: 26;

[0040] Preferably, the above polynucleotide set also includes:

[0041] (III) a third polynucleotide encoding the heavy chain constant region of the monoclonal antibody or antigen-binding fragment thereof of the present invention, preferably, the third polynucleotide is a DNA molecule comprising the nucleotide sequence as shown in SEQ ID NO: 22 (which can encode the heavy chain constant region of the amino acid sequence as shown in SEQ ID NO: 9) or its corresponding mRNA molecule; and,

[0042] (IV) a fourth polynucleotide encoding the light chain constant region of the monoclonal antibody or antigen-binding fragment thereof of the present invention. Preferably, the fourth polynucleotide is a DNA molecule comprising a nucleotide sequence as shown in SEQ ID NO: 23 (which can encode an amino acid sequence as shown in SEQ ID NO: 10 for the light chain constant region) or its corresponding mRNA molecule.

[0043] In the most preferred embodiment, the set of polynucleotides comprises:

[0044] (I) a first polynucleotide encoding the heavy chain of the monoclonal antibody or antigen-binding fragment thereof of the present invention, preferably, the first polynucleotide is a DNA molecule with a nucleotide sequence as shown in SEQ ID NO: 24 or its corresponding mRNA molecule, which can encode the heavy chain with an amino acid sequence as shown in SEQ ID NO: 11; and,

[0045] (II) a second polynucleotide encoding the light chain of the monoclonal antibody or antigen-binding fragment thereof of the present invention. Preferably, the second polynucleotide is a DNA molecule with a nucleotide sequence as shown in SEQ ID NO:25 or its corresponding mRNA molecule, which can encode a light chain with an amino acid sequence as shown in SEQ ID NO:12.

[0046] In a third aspect, the present invention provides a nucleic acid construct comprising the polynucleotide as described in the second aspect above, and, optionally, at least one expression control element operably linked to the polynucleotide.

[0047] In a fourth aspect, the present invention provides a vector comprising the polynucleotide as described in the second aspect above, or the nucleic acid construct as described in the third aspect above.

[0048] The vector of the present invention may be a cloning vector or an expression vector, for example, it may be a plasmid, a cosmid, a phage, etc.

[0049] In some preferred embodiments, the vector is an expression vector, preferably a eukaryotic expression vector.

[0050] In a fifth aspect, the present invention provides a host cell comprising the polynucleotide as described in the second aspect, the nucleic acid construct as described in the third aspect, or the expression vector as described in the fourth aspect;

[0051] The host cell includes, but is not limited to, prokaryotic cells, such as Escherichia coli cells, eukaryotic cells, such as yeast cells, insect cells, plant cells, and animal cells (such as mammalian cells, such as mouse cells, human cells, etc.). The host cell can also be a cell line, such as a 293T cell line.

[0052] Preferably, the host cell is a eukaryotic cell, more preferably a mammalian cell.

[0053] In a sixth aspect, the present invention provides a pharmaceutical composition, comprising the monoclonal antibody or antigen-binding fragment thereof as described in the first aspect, the polynucleotide as described in the second aspect, the nucleic acid construct as described in the third aspect, the expression vector as described in the fourth aspect or the host cell as described in the fifth aspect, and a pharmaceutically acceptable carrier.

[0054] In some feasible embodiments, the pharmaceutical composition is in the form of a nasal spray, an oral preparation, a suppository, or a parenteral preparation;

[0055] Preferably, the nasal spray is selected from aerosols, sprays and powder sprays;

[0056] Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film coatings and ointments;

[0057] Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid preparation or an injectable preparation.

[0058] In a seventh aspect, the present invention provides a kit comprising the monoclonal antibody or antigen-binding fragment thereof as described in the first aspect, the polynucleotide as described in the second aspect, the nucleic acid construct as described in the third aspect, the expression vector as described in the fourth aspect, the host cell as described in the fifth aspect and / or the pharmaceutical composition as described in the sixth aspect.

[0059] In certain preferred embodiments, the kit is a detection or diagnosis kit, wherein the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a detectable label; in certain preferred embodiments, the kit further comprises a second antibody that specifically recognizes the monoclonal antibody or antigen-binding fragment thereof of the present invention or an anti-idiotypic antibody; preferably, the second antibody further comprises a detectable label; such detectable labels are well known to those skilled in the art, and include, but are not limited to, radioactive isotopes, fluorescent substances, luminescent substances, colored substances and enzymes (e.g., horseradish peroxidase), etc.

[0060] In an eighth aspect, the present invention provides a method for preparing the monoclonal antibody or antigen-binding fragment thereof as described in the first aspect above, the method comprising: allowing the host cell as described in the fifth aspect above to express the monoclonal antibody or antigen-binding fragment thereof under conditions suitable for the expression of the monoclonal antibody or antigen-binding fragment thereof, and recovering the expressed monoclonal antibody or antigen-binding fragment thereof from the culture of the host cell.

[0061] In a ninth aspect, the present invention provides the use of the monoclonal antibody or antigen-binding fragment thereof according to the first aspect, the polynucleotide according to the second aspect, the nucleic acid construct according to the third aspect, the expression vector according to the fourth aspect, the host cell according to the fifth aspect, the pharmaceutical composition according to the sixth aspect, and / or the kit according to the seventh aspect in any of the following aspects:

[0062] (1) Use in the preparation of a product for detecting the presence or level of human influenza virus neuraminidase in a sample;

[0063] (2) Use in the preparation of a product for neutralizing the virulence of human influenza virus in a sample;

[0064] (3) Use in the preparation of a medicament for preventing and / or treating a human influenza virus infection or a disease associated with the virus infection in a subject.

[0065] In a tenth aspect, the present invention provides a method for detecting the presence or level of human influenza virus neuraminidase in a sample, the method comprising using the monoclonal antibody or antigen-binding fragment thereof as described in the first aspect, the polynucleotide as described in the second aspect, the nucleic acid construct as described in the third aspect, the expression vector as described in the fourth aspect, the host cell as described in the fifth aspect, the pharmaceutical composition as described in the sixth aspect, and / or the kit as described in the seventh aspect.

[0066] In some preferred embodiments of this method, the monoclonal antibody or antigen-binding fragment thereof further comprises a detectable label.

[0067] In some other preferred embodiments of the method, the method further comprises: using a secondary antibody carrying a detectable label to detect the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0068] The method can be used for diagnostic purposes (eg, the sample is a sample from a patient), or for non-diagnostic purposes (eg, the sample is a cell sample rather than a sample from a patient).

[0069] Therefore, in some specific embodiments, the present invention provides a method for diagnosing whether a subject is infected with human influenza virus, comprising: using the monoclonal antibody or antigen-binding fragment thereof of the present invention as described in the first aspect above to detect the presence of human influenza virus neuraminidase in a sample from the subject; in certain preferred embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a detectable label; in other preferred embodiments, the method further comprises using a second antibody carrying a detectable label to detect the monoclonal antibody or antigen-binding fragment thereof or anti-idiotypic antibody of the present invention.

[0070] The general method of using monoclonal antibodies or their antigen-binding fragments to detect the presence of target viruses or antigens in samples or their levels is well known to those skilled in the art. In certain preferred embodiments, the detection method can use enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay, chemiluminescent immunoassay, radioimmunoassay, fluorescent immunoassay, immunochromatography, competitive method and similar detection methods.

[0071] In an eleventh aspect, the present invention provides a method for neutralizing the virulence of human influenza virus in a sample, comprising: contacting a sample containing human influenza virus with the monoclonal antibody or antigen-binding fragment thereof of the present invention as described in the first aspect above.

[0072] The methods may be used for therapeutic purposes, or for non-therapeutic purposes (eg the sample is a cell sample rather than a patient or a sample from a patient).

[0073] In a twelfth aspect, the present invention provides a method for preventing and / or treating human influenza virus infection or a disease associated with the viral infection in a subject, comprising: administering a preventive and / or therapeutically effective amount of the monoclonal antibody or antigen-binding fragment thereof of the present invention, or the pharmaceutical composition of the present invention to a subject in need thereof.

[0074] In a possible embodiment, the subject is a mammal, such as a human.

[0075] The monoclonal antibodies or antigen-binding fragments thereof of the invention or the pharmaceutical compositions of the invention can be administered to a subject by any appropriate route of administration, including, but not limited to, oral, buccal, sublingual, topical, parenteral, rectal, intrathecal, or nasal routes.

[0076] The medicine or pharmaceutical composition provided by the present invention can be used alone or in combination, and can also be used in combination with other pharmaceutically active agents.

[0077] The "preventively and / or therapeutically effective amount" may vary depending on the subject of administration, the subject organ, symptoms, the method of administration, etc., and can be determined based on the doctor's judgment, taking into account the type of dosage form, the method of administration, the patient's age and weight, the patient's symptoms, etc.

[0078] Beneficial Effects

[0079] The monoclonal antibody of the present invention can specifically bind to the NA protein of human influenza virus with high affinity, and therefore has a very high potential to be developed into a detection antibody for human influenza virus antigens, and may be able to provide a lower detection limit and improve the sensitivity of detection; and the monoclonal antibody of the present invention has a strong neutralizing activity against human influenza virus, can effectively prevent and / or treat human influenza virus infection, and has great clinical application prospects and value. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] One or more embodiments are exemplarily described by the pictures in the accompanying drawings, and these exemplary descriptions do not constitute limitations on the embodiments. The special word "exemplary" here means "used as an example, embodiment or illustrative". Any embodiment described as "exemplary" here is not necessarily interpreted as being superior or better than other embodiments.

[0081] Figure 1 The molecular sieve chromatography results and SDS-PAGE detection results of the monoclonal antibody 18_14D described in Example 2 of the present invention are shown.

[0082] Figure 2 The molecular sieve chromatography results and SDS-PAGE detection results of the monoclonal antibody 18_14D antigen-binding fragment described in Example 3 of the present invention.

[0083] Figure 3 These are the molecular sieve chromatography results and SDS-PAGE detection results of the N6 protein described in Example 4 of the present invention.

[0084] Figure 4 : is the binding kinetic curve of monoclonal antibody 18_14D and N6 protein; wherein, the abscissa is time, in seconds (s); the ordinate is response value, in nM.

[0085] Figure 5 The figure shows the preventive effect of monoclonal antibody 18_14D on influenza virus infection in mice detected by the challenge protection experiment; wherein, the left figure shows the weight change curve of mice after the challenge, and the right figure shows the survival rate curve of mice after the challenge. DETAILED DESCRIPTION

[0086] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution in the embodiment of the present invention will be clearly and completely described below. Obviously, the described embodiment is a part of the embodiment of the present invention, not all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0087] Unless explicitly stated otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0088] The term "and / or" should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0089] The term "percent (%) amino acid sequence identity" or simply "identity" is defined as the percentage of amino acid residues in a candidate amino acid sequence that are identical to the amino acid residues in a reference amino acid sequence, after aligning the amino acid sequences (and introducing gaps, if necessary) to obtain the maximum percentage sequence identity, and not considering any conservative substitutions as part of the sequence identity. Sequence alignments can be performed using various methods in the art to determine percentage amino acid sequence identity.

[0090] The term "antigen-binding fragment" refers to an antigen-binding fragment of an antibody and an antibody analog, which generally includes at least a portion of the antigen-binding region or variable region of the parent antibody, such as one or more CDRs. The antibody fragment retains at least some of the binding specificity of the parent antibody. Specifically, the antigen-binding fragment can be selected from Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2, diabodies, etc.

[0091] The "Fab" fragment consists of a light chain and the CH1 and variable regions of a heavy chain.

[0092] A "Fab'" fragment contains a light chain and a portion of a heavy chain including a VH domain, a CH1 domain, and a portion of the constant region between the CH1 and CH2 domains, with an interchain disulfide bond formed between the two heavy chains of two Fab' fragments to form a F(ab')2 molecule.

[0093] The "F(ab')2" fragment contains two light chains and portions of two heavy chains including a VH domain, a CH1 domain, and a portion of the constant region between the CH1 and CH2 domains, whereby an interchain disulfide bond is formed between the two heavy chains. Thus, the F(ab')2 fragment consists of two Fab' fragments held together by a disulfide bond between the two heavy chains.

[0094] The "Fv" region contains the variable regions from both the heavy and light chains, but lacks the constant regions.

[0095] "Single-chain Fv antibody (scFv antibody)" refers to an antigen-binding fragment comprising the VH and VL domains of an antibody, which domains are contained in a single polypeptide chain. Generally speaking, the scFv polypeptide comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding.

[0096] "Diabodies" are small antigen-binding fragments with two antigen-binding sites. The fragments contain a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL or VL-VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are allowed to pair with the complementary domains of another chain and form two antigen-binding sites.

[0097] The preferred embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that the following examples are provided only for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention. Those skilled in the art may make various modifications and substitutions to the present invention without departing from the purpose and spirit of the present invention.

[0098] The relevant sequence information of the monoclonal antibody 18_14D described in the following examples is shown in Table 1 below.

[0099] Table 1. Sequence information of monoclonal antibody 18_14D

[0100]

[0101]

[0102]

[0103]

[0104]

[0105] Example 1: Screening and sequence identification of antibodies

[0106] With the informed consent signed by the volunteers, the inventors screened a monoclonal antibody capable of binding to the N6 protein from the plasma of volunteers infected with the H5N6 avian influenza virus.

[0107] Specifically, B cells were sorted from PBMCs of volunteers infected with H5N6 avian influenza virus, and CD19 + IgM – IgA – IgD – Single B cells were cultured with 3 cells per well. IgG-positive (capable of secreting IgG antibodies) and antigen-positive (capable of binding H5 or N6 proteins) positive well cells were screened by ELISA. The above cells were lysed, mRNA was extracted, and after reverse transcription into cDNA, the cDNA was used as a template and PCR amplification was performed using human antibody heavy chain and light chain specific primers. The amplified products were subjected to first generation and high-throughput sequencing to obtain the coding genes of the antibody heavy chain variable region and light chain variable region of the B cells in the positive cell wells.

[0108] Since the density of each well is 3 cells, more than one heavy chain variable region gene sequence and more than one light chain variable region gene sequence can be obtained in each well; further, the combination of different heavy chain variable regions and light chain variable regions in the same well was explored, and through efficacy screening, the combination of heavy chain variable region and light chain variable region of a monoclonal antibody was obtained.

[0109] The selected monoclonal antibody is numbered 18_14D, and the nucleic acid coding sequences of the heavy and light chain variable regions are shown in SEQ ID NOs: 20 and 21, respectively, and the amino acid sequences of the heavy chain variable region and the light chain variable region encoded by them are shown in SEQ ID NOs: 7 and 8, respectively. Further, the sequences of the heavy chain variable region and the light chain variable region are analyzed to obtain the amino acid sequences of the three CDRs (HCDR1, HCDR2, HCDR3) of the heavy chain variable region and the three CDRs (LCDR1, LCDR2, LCDR3) of the light chain variable region and their nucleic acid coding sequences; the amino acid sequences of HCDR1, HCDR2, and HCDR3 are shown in SEQ ID NOs: 1, 2, and 3, respectively, and the nucleic acid coding sequences thereof are shown in SEQ ID NOs: 14, 15, and 16, respectively; the amino acid sequences of LCDR1, LCDR2, and LCDR3 are shown in SEQ ID NOs: 4, 5, and 6, respectively, and the nucleic acid coding sequences thereof are shown in SEQ ID NOs: 17, 18, and 19, respectively.

[0110] Example 2: Preparation and purification of monoclonal antibody 18_14D

[0111] 1. Construction of antibody heavy chain / light chain recombinant expression vector

[0112] The nucleotide sequences encoding the heavy chain / light chain variable regions of antibody 18_14D obtained in Example 1 were connected to the nucleotide sequences encoding the constant regions of the heavy chain / λ chain by bridge PCR, and then cloned into the expression vector pCAGGS (purchased from Addgene) to obtain recombinant expression vectors encoding the heavy chain and light chain of the antibody, respectively. The compositions of the constructs expressing the heavy chain and light chain are as follows:

[0113] The heavy chain construct composition (5'-3'): CMV promoter-EcoR I restriction enzyme cleavage site-kozak sequence-leader sequence gene-VH gene-CH gene-Xho I restriction enzyme cleavage site;

[0114] The light chain (λ) construct consists of (5'-3'): CMV promoter - EcoR I restriction enzyme cleavage site - kozak sequence - leader sequence gene - VL gene - CL (c) gene - Xho I restriction enzyme cleavage site;

[0115] Among them, the leading sequence is shown as SEQ ID NO:26, which encodes the amino acid sequence shown as SED ID NO:13; the CH gene sequence is shown as SED ID NO:22, which encodes the amino acid sequence shown as SEQ ID NO:9; the CL gene sequence is shown as SEQ ID NO:23, which encodes the amino acid sequence shown as SED ID NO:10.

[0116] 2. Expression and purification of antibody 18_14D

[0117] The recombinant expression vectors encoding the antibody heavy chain and light chain obtained above were co-transfected into HEK293F cells. The molar ratio of heavy chain and light chain expression plasmids was 1:1.5, and 1 μg plasmid and 3 μg PEI (1 mg mL -1 ). Cells were cultured in SMM 293-TII medium (Sinobiological) at 37°C and 5% CO2, and then supplemented with SMS M293-SUPI (Sinobiological) at a ratio of 35 mL / L 24 and 72 hours after transfection. On the fifth day, the cell supernatant was collected and filtered through a 0.22 μm membrane.

[0118] The filtered cell supernatant was adsorbed by Protein A affinity column (Cytiva) at 4°C, washed with buffer A (20mM Na3PO4, pH=7.4) to remove non-specific binding proteins, and then eluted the target protein from the Protein A affinity column with buffer B (0.1M glycine, pH=3.0), and the eluate at the elution peak was collected for subsequent gel filtration chromatography. The eluate collected at the elution peak was concentrated with a 10kD concentrator and then passed through a Superdex TM 200Increase10 / 300GL column (Cytiva) was used for further purification. During the chromatography, the eluate at the elution peak was collected for SDS-PAGE identification of the target protein. After the target protein was concentrated, the concentration was determined, and the aliquots were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator.

[0119] The gel filtration chromatography and SDS-PAGE identification results of monoclonal antibody 18_14D are as follows: Figure 1 shown by Figure 1 It can be seen that the purity of the obtained antibody can reach more than 95%, and the heavy chain and light chain of the antibody can be seen at about 55kD and 25kD, and the molecular weights are consistent with the theoretical values.

[0120] Example 3: Preparation of monoclonal antibody 18_14D Fab

[0121] In this example, the Fab fragment of monoclonal antibody 18_14D was prepared by the following steps:

[0122] 1. Concentrate the purified monoclonal antibody 18_14D obtained in Example 2 to a concentration of 30 mg / mL or more.

[0123] 2. Calculate the required immobilized papain (agarose resin) (ThermoScientific) according to the mass of the antibody; add papain to the centrifugal column, centrifuge at 2000 rpm / min for 2 min, and discard the supernatant; add enzyme cleavage buffer (20 mM Na3PO4, 10 mM EDTA and 20 mM cysteine, pH = 7.0) to resuspend, centrifuge at 2000 rpm / min for 2 min, and discard the supernatant; repeat washing 3 times.

[0124] 3. Add the antibody from step 1 to the centrifugal column containing papain, and add enzyme cleavage buffer to make the final concentration of the antibody in the antibody-enzyme cleavage system 20 mg / mL. Tighten the lid and invert to mix the enzyme cleavage system. Seal the gap of the centrifugal column with a sealing film and place it on a rotating mixer for enzyme cleavage at 37°C for 6 hours.

[0125] 4. Centrifuge the sample in step 3 and take the supernatant, which is the antibody after enzyme cleavage.

[0126] 5. Use 20mM Na3PO4 to balance the Protein A column, load the digested antibody, collect the flow-through, which is the Fab fragment of the antibody; concentrate the collected Fab fragments, and then pass them through the SuperdexTM200 Increase 10 / 300GL column for gel filtration chromatography to further purify the Fab protein. During the chromatography, collect the eluate at the elution peak for SDS-PAGE identification of the target protein. After the target protein is concentrated, determine the concentration, and store it in a -80℃ refrigerator after quick freezing in liquid nitrogen after packaging.

[0127] The gel filtration chromatography and SDS-PAGE identification results of the monoclonal antibody 18_14D Fab fragment are as follows: Figure 2 shown by Figure 2 It can be seen that the purity of 18_14D Fab can reach more than 95%, and the heavy chain and light chain bands of the antibody Fab fragment can be seen at about 25 kD, and the molecular weights are consistent with the theoretical values.

[0128] Example 4: Expression and purification of N6 protein

[0129] (1) An expression construct comprising a signal peptide, a His tag, a tetramer tag, a thrombin cleavage site and a nucleic acid coding sequence of amino acids 83-470 of the N6 protein (as shown in SEQ ID NO: 27) was cloned into an expression vector pCAGGS to construct a recombinant expression plasmid of the N6 protein.

[0130] SEQ ID NO:27:

[0131]

[0132]

[0133] Among them, the bold part is the nucleic acid coding sequence of the signal peptide, the italic part is the nucleic acid coding sequence of the His tag, the bold+italic part is the nucleic acid coding sequence of the tetramer tag, the underlined part is the nucleic acid coding sequence of the thrombin cleavage site, the bold+italic+underlined part is the stop codon, and the rest is the nucleic acid coding sequence of the amino acid sequence at positions 83-470 of the N6 protein.

[0134] The amino acid sequence expressed is shown in SEQ ID NO: 28:

[0135] Among them, the bold part is the signal peptide, the italic part is the His tag, the bold+italic part is the tetramer tag, the underlined part is the thrombin cleavage site, and the rest is the amino acid sequence of positions 83-470 of the N6 protein.

[0136] (2) The recombinant expression plasmid constructed above was transfected into Expi293F TM The cells were cultured for 5 days, and the cell supernatant was collected by centrifugation. The cell supernatant was filtered through a 0.22 μm filter membrane, and the obtained cell supernatant was adsorbed on a nickel affinity column (His Trap, Cytiva) at 4°C, and washed with buffer A (25 mM Tris, 150 mM NaCl, pH 8.0) and buffer B (25 mM Tris, 150 mM NaCl, pH 8.0, 20 mM imidazole) to remove non-specific binding proteins. The target protein was then eluted from the His Trap with buffer C (25 mM Tris, 150 mM NaCl, pH 8.0, 300 mM imidazole), and the eluate at the elution peak was collected for SDS-PAGE identification of the target protein and subsequent gel filtration chromatography. The eluate collected at the elution peak was concentrated to a final volume of less than 1 ml using a 10kD concentrator tube; the target protein was further purified by gel filtration chromatography using a SuperdexTM200Increase 10 / 300GL column. During the chromatography, the eluate at the elution peak was collected for SDS-PAGE identification of the target protein. After the target protein was concentrated, the concentration was determined, and the aliquots were quickly frozen in liquid nitrogen and stored in a -80°C refrigerator.

[0137] The gel filtration chromatography and SDS-PAGE identification results of N6 protein are as follows Figure 3 As shown; Since the expression construct of N6 protein contains a tetramer tag, it is TM After expression in cells, it will self-assemble into a tetramer form. Figure 3 The elution peak of the gel filtration chromatography curve corresponds to the tetramer of N6 protein; however, after SDS-PAGE electrophoresis, since the protein was denatured, the SDS-PAGE electrophoresis band corresponds to the monomer of N6 protein.

[0138] Figure 3 The results showed that the purity of the obtained N6 protein could reach over 95%, and its molecular weight was consistent with the theoretical value, indicating that the above procedure successfully expressed the N6 protein.

[0139] Example 5: Determination of affinity between the antigen-binding fragment (Fab) of monoclonal antibody 18_14D and N6 protein In this example, the affinity between monoclonal antibody 18_14D and N6 protein was determined by the following steps:

[0140] 1. According to the instructions, the N6 tetramer protein obtained in Example 4 was labeled with biotin (Shanghai Dibai Biotechnology Co., Ltd., H219001).

[0141] 2. Dilute the biotin-labeled N6 tetramer protein to 20 μg / mL.

[0142] 3. Use PBS-T solution to dilute 18_14D Fab 2-fold to 200nM, 100nM, 50nM, 25nM, 12.5nM, and 6.25nM.

[0143] 4. Use the ForteBio Octet Red instrument to fix the biotin-labeled N6 tetramer onto the SA sensor, measure the binding and dissociation of 18_14D Fab and N6 tetramer protein, and calculate the affinity.

[0144] The results are as follows Figure 4 As shown by Figure 4 It can be seen that 18_14D Fab has a high affinity with N6 protein, with an affinity of 26nM.

[0145] Example 6: Preventive effect of monoclonal antibody 18_14D on live influenza virus H5N6 infection in mice

[0146] In order to detect the preventive and protective effect of 18_14D antibody on mice, we conducted an animal challenge and protection experiment.

[0147] The animals used in the challenge and protection experiment were Balb / c mice, which were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. All of them were female and 6-8 weeks old.

[0148] The virus used in the challenge protection experiment is influenza virus H5N6 (A / Yunan / DQ001 / 2015, GISAID ID:EPI_ISL_200837) (abbreviated as DQ001), which is recorded in the article "Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in China, 2016, Cell Host & Microbe 20 (6) DOI: 10.1016 / j.chom.2016.10.022". The public can obtain it from the applicant and can only be used to repeat the experiment of the present invention and cannot be used for other purposes.

[0149] The specific experimental groups and infection methods are shown in Table 1.

[0150] Table 1. Experimental groups and challenge methods for evaluating the preventive effect of 18_14D monoclonal antibody on mice

[0151]

[0152] Within 14 days after infection, the weight changes and survival status of mice in each group were measured, and the weight change curves and survival rate curves were drawn.

[0153] The weight change curves and survival rate curves of each group of mice after challenge are shown in Figure 2. Figure 5 As shown in the left and right figures.

[0154] Figure 5 The results showed that mice were intraperitoneally injected with 20 mg / kg of antibody 3 hours before H5N6 challenge and then challenged with a lethal dose (3LD 50 ) virus, all mice (6 / 6) survived, with a protection rate of 100%; 3 hours before H5N6 challenge, mice were intraperitoneally injected with 1mg / kg or 5mg / kg of antibody and then challenged with a lethal dose (3LD 50 ) virus, 5 out of 6 mice survived.

[0155] The above data show that the 18_14D antibody can effectively prevent influenza virus infection and significantly reduce the severity and mortality rate caused by influenza virus infection (at an appropriate concentration, a 100% protection effect can be achieved).

[0156] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A monoclonal antibody or an antigen-binding fragment thereof that specifically binds to human influenza virus neuraminidase, comprising a heavy chain variable region and / or a light chain variable region, wherein: The heavy chain variable region comprises: HCDR1, HCDR2 and HCDR3 whose amino acid sequences are shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively; The light chain variable region comprises: The amino acid sequences of LCDR1, LCDR2 and LCDR3 are shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 respectively; wherein the amino acid sequence of SEQ ID NO:5 is DVS.

2. The monoclonal antibody or antigen-binding fragment thereof according to claim 1, wherein The antibody or antigen-binding fragment thereof comprises: a heavy chain variable region comprising, or consisting of, the amino acid sequence shown in SEQ ID NO:7, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence shown in SEQ ID NO:7; and, A light chain variable region comprising, or consisting of, the amino acid sequence shown in SEQ ID NO:8, or an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:

8.

3. The monoclonal antibody or antigen-binding fragment thereof according to claim 2, wherein: The antibody or antigen-binding fragment thereof comprises: A heavy chain variable region, the amino acid sequence of which is shown in SEQ ID NO:7; and, The light chain variable region, whose amino acid sequence is shown in SEQ ID NO:

8.

4. The monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein: The antibody or antigen-binding fragment thereof further comprises a constant region; Preferably, the constant region comprises a heavy chain constant region as shown in SEQ ID NO:9 and a light chain constant region as shown in SEQ ID NO:

10.

5. The monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, wherein: The antibody or antigen-binding fragment thereof comprises: a heavy chain comprising, or consisting of, the amino acid sequence shown in SEQ ID NO: 11, or an amino acid sequence having at least 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to the amino acid sequence shown in SEQ ID NO: 11; and, A light chain comprising, or consisting of, the amino acid sequence shown in SEQ ID NO:12, or an amino acid sequence having at least 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:

12.

6. The monoclonal antibody or antigen-binding fragment thereof according to claim 5, wherein The antibody or antigen-binding fragment thereof comprises: A heavy chain, the amino acid sequence of which is shown in SEQ ID NO: 11; and The light chain has an amino acid sequence as shown in SEQ ID NO:

12.

7. The monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein: The antigen binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single chain antibody, human antibody, chimeric antibody or bispecific or multispecific antibody.

8. A polynucleotide encoding the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

9. The polynucleotide according to claim 8, wherein The polynucleotide is a polynucleotide group, and the polynucleotide group includes: (I) a DNA molecule comprising a nucleotide sequence as shown in SEQ ID NO: 14, 15, 16 or its corresponding mRNA molecule; and, (II) A DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 17, 18, 19 or its corresponding mRNA molecule.

10. The polynucleotide according to claim 9, wherein The polynucleotide set comprises: (I) a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 20 or its corresponding mRNA molecule; and, (II) a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 21 or its corresponding mRNA molecule; Preferably, the polynucleotide set further comprises: (III) a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 22 or its corresponding mRNA molecule; and, (IV) a DNA molecule comprising the nucleotide sequence shown in SEQ ID NO: 23 or its corresponding mRNA molecule.

11. The polynucleotide according to claim 10, wherein The polynucleotide set comprises: (I) a DNA molecule with a nucleotide sequence as shown in SEQ ID NO: 24 or its corresponding mRNA molecule; and, (II) A DNA molecule having a nucleotide sequence as shown in SEQ ID NO: 25 or its corresponding mRNA molecule.

12. A nucleic acid construct comprising a polynucleotide according to any one of claims 8 to 11 and, optionally, at least one expression control element operably linked to the polynucleotide.

13. A vector comprising the polynucleotide according to any one of claims 8 to 11, or the nucleic acid construct according to claim 12; Preferably, the vector is an expression vector, more preferably a eukaryotic expression vector.

14. A host cell comprising the polynucleotide according to any one of claims 8 to 11, the nucleic acid construct according to claim 12 or the expression vector according to claim 13; Preferably, the host cell is a eukaryotic cell; More preferably, the host cell is a mammalian cell.

15. A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the polynucleotide according to any one of claims 8 to 11, the nucleic acid construct according to claim 12, the expression vector according to claim 13 or the host cell according to claim 14, and a pharmaceutically acceptable carrier.

16. The pharmaceutical composition according to claim 15, wherein The pharmaceutical composition is in the form of a nasal spray, an oral preparation, a suppository or a parenteral preparation; Preferably, the nasal spray is selected from aerosols, sprays and powder sprays; Preferably, the oral preparation is selected from tablets, powders, pills, granules, soft / hard capsules, film coatings and ointments; Preferably, the parenteral preparation is a transdermal preparation, an ointment, a plaster, an external liquid or an injectable preparation.

17. A kit comprising the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the polynucleotide according to any one of claims 8 to 11, the nucleic acid construct according to claim 12, the expression vector according to claim 13, the host cell according to claim 14 and / or the pharmaceutical composition according to claim 15 or 16.

18. A method for preparing the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the method comprising: The host cell of claim 14 is allowed to express the monoclonal antibody or the antigen-binding fragment thereof under conditions suitable for the expression of the monoclonal antibody or the antigen-binding fragment thereof, and the expressed monoclonal antibody or the antigen-binding fragment thereof is recovered from the culture of the host cell.

19. Use of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, the polynucleotide according to any one of claims 8 to 11, the nucleic acid construct according to claim 12, the expression vector according to claim 13, the host cell according to claim 14, the pharmaceutical composition according to claim 15 or 16, and / or the kit according to claim 17 in any of the following aspects: (1) Use in the preparation of a product for detecting the presence or level of human influenza virus neuraminidase in a sample; (2) Use in the preparation of a product for neutralizing the virulence of human influenza virus in a sample; (3) Use in the preparation of a medicament for preventing and / or treating a human influenza virus infection or a disease associated with the virus infection in a subject.

Citation Information

Patent Citations

  • Monoclonal antibody for identifying N6 subtype avian influenza virus neuraminidase protein and application of monoclonal antibody

    CN111117970A

  • Fully human antibody for broad-spectrum neutralization of influenza virus

    CN111423507A

  • Monoclonal antibodies capable of broad-spectrum identification of influenza A virus NP protein and application thereof

    CN113024666A

  • Antibody aiming at H5 subtype as well as preparation method and application thereof

    CN117886930A

  • Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses

    US20130004505A1

Cited By

  • Influenza A virus antibody as well as preparation method and application thereof

    CN119954944A

  • Composition for regulating overall metabolic balance, inhibiting cancer cell growth and resisting tumors

    CN121243342A

  • Single-domain antibody for inhibiting neuraminidase activity of influenza B virus and application of single-domain antibody

    CN121895457A

  • Humanized monoclonal neutralizing antibody targeting metapneumovirus F protein and application thereof

    CN122255263A